NEW YORK, June 19, 2018 /PRNewswire/ -- WeissLaw LLP
is investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of Foundation Medicine,
Inc. ("FMI" or the "Company") (NASDAQ: FMI) in connection with the
proposed acquisition of the Company by Swiss healthcare company
Roche Holding AG ("Roche"). Under the terms of the agreement,
FMI shareholders will receive $137.00
in cash for each FMI share they own.
WeissLaw is investigating whether FMI's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, according to Bloomberg, the deal "may be a
disappointment to investors," and is unusual as three of Roche's
best-selling drugs are expected to face competition from generics
in the next few years. Moreover, the acquisition of FMI, a
leader in molecular information and personalized cancer care, is a
strategic transaction that Roche hopes will drive its treatment
success rate. According to Daniel
O'Day, CEO of Roche Pharmaceuticals, "[t]his is important to
our personalised healthcare strategy as we believe molecular
insights and the broad availability of high quality comprehensive
genomic profiling are key enablers for the development of, and
access to, new cancer treatments."
Given these facts, WeissLaw is investigating whether FMI's Board
acted in the best interests of FMI's public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own FMI shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Joshua Rubin by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the
form on our website,
http://www.weisslawllp.com/foundation-medicine-inc/
View original
content:http://www.prnewswire.com/news-releases/weisslaw-llp-foundation-medicine-inc-acquisition-may-not-be-in-the-best-interest-of-fmi-shareholders-300669019.html
SOURCE WeissLaw LLP